Wednesday December 12, 2018 04:27

LINDE Press Releases

Alfresco Drinking in December General—04 Dec 18

Welcome the Festive Season with our holiday drinks. Stay cool in December with Ho Ho Ho! and Fresh & Crisp, two cocktails with a fresh touch of mint, specially crafted by Mixologist Khun Korn. Ho Ho Ho! - Evan Williams Bourbon, Mulled Red Wine, Mint

People With Diabetes May Achieve Improved Glycaemic Control With Tresiba(R) Versus Glargine U100, Without an Increase in Hypoglycaemia Heathcare—02 Oct 18

BERLIN--2 Oct--PRNewswire/InfoQuest

According to results of a post-hoc analysis people with both type 1 and type 2 diabetes in clinical practice may achieve improved glycaemic control (HbA1c) with Tresiba(R) (insulin degludec) versus insulin glargine U100, without an increase in hypoglycaemia (potentially dangerous low blood sugar).[1] The results of this new analysis from the SWITCH 1 and 2 trials were presented today at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD 2018) in Berlin, Germany.

Lowering blood sugar to target levels is important to help prevent the complications of diabetes, but reductions can increase the risk of hypoglycaemia. In this post-hoc analysis, based on the reduction in hypoglycaemia risk with Tresiba(R) found in the maintenance period of the SWITCH trials, it is estimated that people with diabetes may achieve a mean HbA1c reduction of 0.70% (type 1 diabetes) and 0.96% (type 2 diabetes) with Tresiba(R) compared to insulin glargine U100 at similar rates of hypoglycaemia.[1]

"Episodes of hypoglycaemia can be dangerous for people with diabetes and can often be a significant barrier to achieving glycaemic control," said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. "These findings add to already published evidence showing a r

The Linde Group โชว์ความเป็นเลิศด้านเทคโนโลยีก๊าซ ที่งาน 2018 World Congress on Powder Metallurgy ทั่วไป—18 Sep 18

The Linde Group กลุ่มบริษัทด้านเทคโนโลยี ได้เข้าร่วมงาน 2018 World Congress on Powder Metallurgy (WORLDPM2018) ณ กรุงปักกิ่ง เพื่อนำเสนอโซลูชั่นสำหรับกรรมวิธีโลหะผงและการผลิตแบบเพิ่มเนื้อวัสดุ (additive manufacturing)

Gas-enabled Excellence: The Linde Group#s Presence on 2018 World Congress on Powder Metallurgy General—17 Sep 18

The technology company The Linde Group is showcasing on 2018 World Congress on Powder Metallurgy (WORLDPM2018) in Beijing with its complete offer of solutions for powder metallurgy and additive manufacturing throughout the industry value chain. A great

Linde#s Hydrogen-Powered Mobility Technology To Support Zero-Emission Vehicles in Stcoks—05 Sep 18

- Clean fuel alternatives for Malaysia's automotive industry with the set-up of Linde-Sarawak Energy Berhad hydrogen production plant and refuelling station in Sarawak. - Linde is the technology leader for end-to-end sustainable hydrogen solutions. -

แถลงการณ์บริษัท ทาทา มอเตอร์ส ยานยนต์—03 Aug 18

สืบเนื่องจากนโยบายการปรับกลยุทธ์ 2.0 ทาทา มอเตอร์ส ได้จัดทำกลยุทธ์ที่เรียกว่า 6 การขับเคลื่อน (6-Cylinder Strategy) เพื่อก่อให้เกิดความยั่งยืน ความสามารถในการแข่งขันและการเติบโตของกระแสเงินสด หนึ่งในนั้นได้แก่เรื่อง "หนี้สินสุทธิ" และ

Lunch for students at the Pattaya Redemptorist School for the Blind General—31 Jul 18

Dusit Thani Pattaya joined the nation as it celebrated the month of July, marking H.M. King Maha Vajiralongkorn's birthday on 28 July. Celebrations began with an alms giving ceremony for nine monks from Djitthabhawan Temple in the early morning attended

Significant Blood Sugar Improvement With Xultophy(R) Compared to Insulin Glargine U-100 When Used Heathcare—25 Jun 18

Adults with type 2 diabetes treated with Xultophy(R) (insulin degludec and liraglutide injection) also experienced no change in body weight, lower rates of hypoglycaemia and a lower insulin dose at 26 weeks Xultophy(R) (insulin degludec and liraglutide

Tresiba(R) Demonstrated Significantly Improved Blood Sugar Control and Lower Rates of Hypoglycaemia Heathcare—25 Jun 18

Adults with type 2 diabetes treated with Tresiba(R) (insulin degludec injection) had a significant reduction in HbA1c and a 30% lower rate of hypoglycaemic episodes after starting basal insulin Findings from CONFIRM - a large real-world evidence (RWE)

SET announces SET Index Series semi-annual review results to be used in second half of Stcoks—19 Jun 18

The Stock Exchange of Thailand (SET) announces, the semi-annual index review results for the SET50, SET100, sSET, SETHD indices, and index's constituents of SETCLMV and SETTHSI to be used in the second half of 2018 (July 1 - December 31). There will be

Judicial independence in Philippines is under threat, says UN human rights General—01 Jun 18

A UN human rights expert has expressed grave concerns about public threats issued against the Philippines' Chief Justice by the country's President, saying her dismissal, that followed those threats, is sending a chilling message to other supreme court

TMB credit card offers you unlimited shopping at Index Living Mall. Receive a rebate and a maximum Stcoks—07 May 18

TMB credit card gives home lovers unlimited shopping for all furniture and home decors at all Index Living Malls, Index Furniture Center at Fashion Island and The Mall Bangkae, Winner Furniture at Seacon Square, The Mall Tha Phra and Central Bangna (TMB

เสียงแห่งแสงสว่าง พบกับคนดีเปลี่ยนโลก ณัฐวุฒิ อมรวิวัฒน์ ผู้สร้างแอปฯ Read For the Blind ทางช่อง บันเทิง—24 Apr 18

ทำดีต้องบอกต่อ คนดีต้องสรรเสริญ ติดตามเรื่องราวความรู้สึกดีๆ กับยามเช้าวันใหม่ได้ ในรายการ "ทันข่าวเช้า" ช่วง "คนดีเปลี่ยนโลก" (Man Change The World) พบกับอีกหนึ่งเรื่องราวการทำดีไม่หวังสิ่งตอบแทน และจิตใจอาสาเพื่อคนด้อยโอกาส ในวันพฤหัสบดีที่ 26 เมษายน

Swift Biosciences เปิดตัวผลิตภัณฑ์ Unique Dual Indexing Kits มุ่งปรับปรุงเทคโนโลยี Multiplexed Next สุขภาพ—09 Apr 18

- ผลิตภัณฑ์ Accel-NGS Unique Dual Indexing Kits แบบใหม่ ช่วยลดความผิดพลาดของการอ่านตำแหน่งที่ไม่ถูกต้องเพื่อผลลัพธ์ที่มีคุณภาพสูงขึ้น Swift Biosciences ประกาศเปิดตัวผลิตภัณฑ์ Accel-NGS(R) Unique Dual Indexing Kits

Swift Biosciences Launches Unique Dual Indexing Kits to Improve Multiplexed Next Generation Heathcare—09 Apr 18

- New Accel-NGS Unique Dual Indexing Kits minimize read misassignments for higher quality results Swift Biosciences today announced the launch of its Accel-NGS(R) Unique Dual Indexing Kits , which deliver the power and value of high-throughput

Linden Unified School District, CA GO Bond Rating Raised To #AA-# On Strong Tax Base, Stable To Stcoks—06 Mar 18

SAN FRANCISCO (S&P Global Ratings) March 5, 2018--S&P Global Ratings raised its long-term rating to 'AA-' from 'A+' on Linden Unified School District, Calif.'s general obligation (GO) bonds and removed the rating from CreditWatch with negative

Natural Elements-Inspired Uniqlo U Spring/Summer 2018 Collection to Launch from January General—26 Jan 18

UNIQLO launches that its Spring/Summer 2018 Uniqlo U collection will launch from January 26 next year. Available at UNIQLO stores and at UNIQLO.com, the range embodies the LifeWear philosophy of creating high-quality clothing that is universal in design

Photo Release: Hilton Pattaya Donates Used Calendars and Audio Fable for the General—19 Jan 18

Hilton Pattaya led by Mr.Montree Sattham, Director of Human Resources, Thailand together with team members recently organized "Calendar for the Blind" by donating used calendar and audio fable to Pattaya Redemptorist School for the Blind, for the 4th

SET announces SET indices semi-annual review results to be used in first half of Stcoks—13 Dec 17

The Stock Exchange of Thailand (SET) announces the semi-annual index review results for the SET50, SET100, sSET and SETHD indices to be used in the first half of 2018 (Jan 1 - June 30). There will be 6 additions to SET50 Index,13 additions to SET100

Xultophy(R) Significantly Reduces Blood Sugar Levels, Body Weight and Risk of Hypoglycaemia for Heathcare—12 Dec 17

Newly published data from real-world European clinical practice has shown that Xultophy(R) (insulin degludec/liraglutide) significantly reduced blood sugar levels in people with type 2 diabetes after six months.[1] The study looked at people with type 2

Ryzodeg(R) Significantly Reduces the Risk of Low Blood Sugar in People With Type 2 Diabetes who Heathcare—07 Dec 17

In people with type 2 diabetes who fast during Ramadan, Ryzodeg(R) (insulin degludec/insulin aspart) reduced the overall rate of low blood sugar (hypoglycaemia) including severe episodes by 62% and the rate of nocturnal hypoglycaemia by 74% versus

Preliminary Ratings Assigned To Six Classes From KVK CLO 2013-1 Ltd. In Connection With Proposed Stcoks—07 Dec 17

- We reviewed KVK CLO 2013-1 Ltd./KVK CLO 2013-1 LLC, which, based on its proposed supplemental indenture, is expected to refinance its class A, B, C, D, and E notes on Dec. 13, 2017, through an optional redemption and replacement note issuance. - After

Preliminary Ratings Assigned To Two Classes From Stewart Park CLO Ltd. In Connection With Proposed Stcoks—06 Dec 17

- We reviewed Stewart Park CLO Ltd./Stewart Park CLO LLC, which, based on its proposed supplemental indenture, is expected to refinance its class A, B, C, D, and E notes on Jan. 16, 2018, through an optional redemption and replacement note issuance. -

Xultophy(R) Reported a Better Option than Basal-Bolus Insulin Therapy to Manage Type 2 Diabetes by Heathcare—06 Dec 17

Once-daily Xultophy(R) (insulin degludec/liraglutide) was a better option to manage diabetes compared to multiple daily injections of insulin (basal-bolus regimen). This was reported by people with type 2 diabetes whose blood sugar was not controlled on

XCMG Hydraulic Cylinder Sets New Record with 9,500 Non-stop Working Energy—04 Dec 17

A hydraulic cylinder for large-tonnage excavators developed by XCMG Hydraulics Co., Ltd has reported 9,500 continuous working hours in Pilbara Region, Australia, smashing the previous 5,000-hour record with its outstanding performance under a range of

Xultophy(R) Offers Greater Blood Sugar and Body Weight Reductions in People With Type 2 Diabetes, Heathcare—04 Dec 17

New findings from an indirect comparison between Xultophy(R) and IGlarLixi published in the Journal of Medical Economics show that treatment with Xultophy(R) (insulin degludec/liraglutide) provides statistically significant greater reductions in blood

Switching to Tresiba(R) is Highly Cost-effective and Cost-saving in a Real-world Heathcare—06 Nov 17

A new analysis of real-world data has shown that switching to Tresiba(R) (insulin degludec) is highly cost-effective and cost-saving for the treatment of type 1 and type 2 diabetes, respectively.[1] The analysis was presented today at the International

Photo Release: Canon announces winners of CanonLife Redefine 2: The Thai Alphabetical Indexes photo IT—31 Oct 17

Canon Marketing (Thailand) Co., Ltd. has recently announced the winners of "CanonLife Redefine 2: The Thai Alphabetical Indexes" online photo contest encouraging photography enthusiasts to submit creative photographs that represent any of the Thai

Canon announces winners of CanonLife Redefine 2: The Thai Alphabetical Indexes photo IT—30 Oct 17

Canon has announced the winners of "CanonLife Redefine 2: The Thai Alphabetical Indexes" online photo contest encouraging photography enthusiasts to submit creative photographs that represent any of the Thai alphabet and depict any of the royal projects